


# The world's leading CRO

## Powered by Healthcare Intelligence

ICON is the world's largest and most comprehensive clinical research organisation, but we're more than just a CRO. We know it requires more action beyond "status quo" in order to guide our customers through the ever-evolving landscape of clinical drug development. Powered by Healthcare Intelligence - the harmonisation of experience, expertise, insights, data, and technology - we strategically and proactively solve today's challenges without losing sight of their impact tomorrow.

From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives.

ICON offers the most comprehensive suite of integrated clinical development services in the industry. We've designed fully customisable solutions to help our customers achieve their goals across a seamless delivery model spanning their product's entire lifecycle.





ICON has established relationships with a majority of the world's top pharmaceutical and biotech companies, offering:

**Scale:** With an expansive portfolio of integrated clinical, commercialisation and consulting services, global presence, depth in therapeutic expertise, and data-driven healthcare technology, we deliver globally scaled expertise & solutions for all customers and patients. ICON is:

- World leader in Functional Service Provision (FSP)
- Global number 2 in full service Ph 2/3 clinical research
- Global number 2 in Early Phase clinical research
- Global number 3 in Late Phase & RWE
- Global number 4 in Central & Speciality Laboratory Services

**Focus:** With no ownership from a parent organisation with different business lines or models, and no distractions from 'near adjacencies', we are completely committed to achieving clients' clinical development programs. Our 40,500+ employees have a singular focus on successful clinical research and commercialisation, leveraging transformational technology and innovation to execute clinical trials from Phase 1 to post-approval studies with the highest quality, expertise and speed.

**Speed to market:** Our extensive services portfolio, digital and data technology capabilities, and enhanced access to more diverse patient populations, have been combined with flexible delivery approaches and partnership models – all with the aim of reducing development time and costs.

**Flexible partnership models:** We have partnerships with a majority of the world's top biopharma and biotech companies worldwide. We are the global leader in Functional Service Provision and a top global provider of full service clinical research. Regardless of the size of your organisation or your project, we work your way.

**Delivering integrated decentralised clinical trials:** Clinical research should engage with patients wherever they are. ICON's customised, integrated decentralised clinical trial solutions can help you achieve better outcomes, while maximising recruitment and retention of diverse patient populations.

ICON has all the service components to deliver decentralised clinical trials and the experience and expertise to provide integrated, customised solutions.

**Access to patients:** Patients are at the heart of everything we do at ICON. We provide the most comprehensive and connected patient journeys across the largest and most diverse patient populations. Our site networks, patient recruitment expertise, and in-home services unlock access to millions of patients. ICON streamlines the clinical trial process, accelerating study-startup, and ensuring patient recruitment and retention meet or exceed targets.

ICON offers customers enhanced access to a larger global pool of more diverse patients through its global site network (Accellacare), specialised oncology network (Oncacare), a paediatric site network, in-home services and a network of six Phase I clinical research units across the United States and Europe.

**Quality:** The quality of our work is vital to our mission of bringing better medications to patients around the world. We are committed to maintaining, supporting, checking and improving our quality systems to exceed the quality standards demanded by our clients, patients and regulatory authorities. ICON's Quality Management System (QMS) comprises our mechanisms for ensuring that all our services are performed to the highest ethical standards, conform to all relevant regulatory requirements and satisfies contractual obligations.

**Emerging therapies:** ICON offers deep experience in the unique challenges of developing emerging treatments such as Immuno-oncology and other cell and gene therapies, with several approved treatments already on the market.

**With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 113 locations in 53 countries as at September 30, 2022.**